Cawston T, Carrere S, Catterall J, Duggleby R, Elliott S, Shingleton B, Rowan A
Department of Rheumatology, Department of Medicine, University of Newcastle, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
Novartis Found Symp. 2001;234:205-18; discussion 218-28. doi: 10.1002/0470868678.ch13.
The matrix metalloproteinases (MMPs) are a unique family of metalloenzymes that, once activated, can destroy connective tissue. The active enzymes are all inhibited by tissue inhibitors of metalloproteinases (TIMPs). The relative amounts of active MMPs and TIMPs are important in determining whether tissues are broken down in disease. Although elastase is often regarded as the target enzyme in chronic obstructive pulmonary disease (COPD), both the neutrophils and macrophages in the lung contain metalloproteinases and both collagen and elastin are degraded in disease. Transgenic studies have shown that when MMP1 is over-expressed, pulmonary emphysema develops in mice, while MMP12 knockout mice do not develop pulmonary emphysema when exposed to cigarette smoke. New drugs that can specifically block active MMPs are now available. These potent inhibitors are effective in vitro and prevent the destruction of tissue in animal models. Future patient trials will test the effectiveness of these compounds in preventing tissue destruction.
基质金属蛋白酶(MMPs)是一类独特的金属酶家族,一旦被激活,就能破坏结缔组织。活性酶均受到金属蛋白酶组织抑制剂(TIMPs)的抑制。活性MMPs和TIMPs的相对含量对于确定疾病中组织是否会被分解至关重要。尽管弹性蛋白酶常被视为慢性阻塞性肺疾病(COPD)中的靶酶,但肺中的中性粒细胞和巨噬细胞都含有金属蛋白酶,且在疾病中胶原蛋白和弹性蛋白都会被降解。转基因研究表明,当MMP1过度表达时,小鼠会发生肺气肿,而MMP12基因敲除小鼠在接触香烟烟雾时不会发生肺气肿。现在已有能特异性阻断活性MMPs的新药。这些强效抑制剂在体外有效,并能防止动物模型中的组织破坏。未来的患者试验将测试这些化合物在预防组织破坏方面的有效性。